Why the study?
Heart failure prognosis without therapy is poor, prompting a systematic review to evaluate the effects and safety of SGLT2 inhibitors in these patients.
Do SGLT2 inhibitors improve outcomes and safety compared to placebo in patients with heart failure?
Population
Heart failure patients across nine RCTs
Comparison
SGLT2 inhibitors (empagliflozin or dapagliflozin) vs placebo
Design
Systematic review and meta-analysis of randomized controlled trials
Authors
Loading...
Supports SGLT2i as foundational HF therapy; confirms mortality and hospitalization reductions across trials.
Do SGLT2 inhibitors improve outcomes and safety compared to placebo in patients with heart failure?
SGLT2 inhibitors significantly reduce all-cause and cardiovascular mortality, as well as heart failure hospitalizations, in patients with heart failure.
Chambergo‐Michilot et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: